ERX-208 / EtiraRx - LARVOL DELTA

Preclinical Data on ERX-208 and ERX-315 to Be Presented at AACR 2025 (ABN Newswire) - "Etira announced three presentations at the AACR Annual Meeting 2025 featuring new preclinical data on its LIPA-targeting compounds ERX-208 and ERX-315....Three presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 showcase the ongoing development of Etira's platform that targets lysosomal acid lipase A (LIPA) to induce endoplasmic reticulum (ER) stress and cell death in cancer."

Preclinical • Hepatocellular Cancer • Ovarian Cancer

Optimization of the LIPA targeting agent for the treatment of ovarian cancer (AACR 2025) - "Recent findings indicate that elevated basal levels of endoplasmic reticulum stress (ERS) in OCa represent a significant vulnerability and identified LIPA as a novel target for inducing ERS in cancer cells with the oligobenzamide ERX-41. These findings suggest that ERX-208 is a promising candidate as a therapeutic agent in OCa treatment. Since a related analog of ERX-208, ERX-315 is in clinical trials, these data strongly support the evaluation of ERX-208 in patients with OCa."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5

Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancer (AACR 2024) - "Collectively, our findings underscore the preclinical promise of ERX-208 as a potential therapeutic agent for treating OCa. Conflict: The patents surrounding ERX-208 are licensed to EtiraRx."

Preclinical • Colorectal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5

ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress (AACR 2023) - "Collectively, our results demonstrated the utility of ERX-208 and will establish a novel therapeutic paradigm in OCa that overcomes tumor heterogeneity by targeting LIPA and enhancing ERS leading to apoptosis."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5 • XBP1